Careful patient selection, monitoring, and follow-up remain essential
doi: 10.1186/s12891-022-05396-5 Summary Keywords type 2 diabetes, osteoporosis, GLP-1 receptor agonists, electronic medical records, cohort study, bone metabolism, fracture risk Citation Chen M, Lyu Y, Zhao J, Han X, Huang T, Yang T and Zhou Y (2025) Use of GLP-1 receptor agonist and risk of osteoporosis among patients with type 2 diabetes: a real-world study
The FDA has identified serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilatory reaction
If your answer is yes to any of these questions, it is important to seek medical advice
doi: 10.4103/1673-5374.272620 101 HellstrmPM